Hikma and Vectura ally on Ellipta rivals
Executive Summary
Hikma has announced a global development and marketing collaboration deal with Vectura aimed at developing generic versions of GlaxoSmlithKline’s (GSK’s) Ellipta respiratory portfolio. The agreement on rivals to Ellipta – which builds on an existing collaboration between the two firms to develop a generic version of GSK’s Advair Diskus (fluticasone/salmeterol) – will use Vectura’s proprietary ‘open-inhale-close’ dry-powder inhaler device.
You may also be interested in...
Hikma Is Prepared For Tougher Pricing Environment In 2022
Hikma is prepared for additional competitors on key products as well as growing price pressure in the US, CEO Siggi Olafsson tells Generics Bulletin in the second part of an exclusive interview.
Hikma Still Sees Value In Generic Advair Despite Teva’s US Approval
Hikma expects healthy prospects for its US Advair generic in 2022, despite rival Teva recently receiving FDA approval for its own version. Meanwhile, Hikma CEO Siggi Olafsson also outlined expectations for generic competition on icosapent amid ongoing API shortages.
Philip Morris Closes In On Vectura As £1.1bn Offer Passes Threshold
Philip Morris once again pledged to up R&D in Vectura after its £1.1bn takeover offer for the UK-based inhalation specialist became unconditional, following the tobacco giant’s acrimonious face-off with private equity Carlyle earlier this year.